11月21日，在第十九届钱江心血管病会议（QICC 2025）现场，丁香园与全球心血管领域顶尖期刊《美 国心脏病学会杂志》（简称JACC）共同举行了战略合作一周年回顾暨深化合作仪式，双方回顾了合作 一周年的丰硕成果，并就未来在AI学术协作中的应用合作进行探讨。大会主席、中国科学院院士、浙 江大学医学院附属第二医院院长王建安教授、耶鲁大学医学院、《JACC》主编Harlan KRUMHOLZ教 授、中华医学会杂志社副社长刘冰教授、丁香园创始人、董事长李天天等出席了活动仪式。 在一周年活动现场，耶鲁大学医学院Harlan M. Krumholz教授分享他对双方合作一年的感受与展望， Harlan表示，与丁香园的合作具有深远意义，JACC借助丁香园平台与中国医生、学者有了更为紧密的 联系，期刊也能更好的为中国临床医生提供强有力的支持。大会主席、中国科学院院士、浙江大学医学 院附属第二医院院长王建安教授也在现场进行了致辞。除探讨东西方的学术交流外，大会组委会还邀请 了中华医学会杂志社副社长刘冰教授，参与了中外期刊发展交流与传播互鉴专题讨论。 一周年的合作里程碑，不仅是回顾，更是新篇章的起点。作为中国医疗健康领域的领军 ...

Group 1 - The company, 医脉通 (02192), announced the issuance of 534,500 ordinary shares to a director exercising stock options under the pre-IPO stock option plan adopted on March 29, 2021 [1]

Group 1 - The core point of the article is that Franklin Templeton has increased its stake in the company Medlinker (02192) by acquiring 1.6715 million shares at a price of HKD 14.5086 per share, totaling approximately HKD 24.2511 million [1] - After the acquisition, Franklin Templeton's total shareholding in Medlinker is now 37.3465 million shares, representing a 5.09% ownership stake [1]

Core Insights - The company reported better-than-expected performance for 1H25, with revenue of 312 million yuan (+28.2% YoY) and net profit attributable to shareholders of 166 million yuan (+4.3% YoY) [1][2] - The growth in revenue is attributed to a rapid increase in the number of collaborative projects [1] Financial Performance - Non-IFRS EBIT for 1H25 reached 72.69 million yuan (+36.4% YoY), with a corresponding profit margin of 23.3% (+1.4 percentage points YoY) [1][2] - The gross margin for 1H25 was reported at 59.0% (-1.6 percentage points YoY), influenced by increased costs associated with digital marketing projects for pharmaceutical clients [2] Revenue Breakdown - Revenue by business segment for 1H25: Precision Marketing and Enterprise Solutions at 292 million yuan (+29.6% YoY), Medical Knowledge Solutions at 9.195 million yuan (+9.2% YoY), and Intelligent Patient Management Solutions at 10.46 million yuan (+11.5% YoY) [1] - Revenue by region for 1H25: Domestic revenue at 304 million yuan (+28.0% YoY) and overseas revenue at 77.55 million yuan (+37.5% YoY) [1] Client Engagement - The number of clients covered by Precision Education and Enterprise Solutions increased to 191 (+20.9% YoY), with a total of 445 projects (+32.4% YoY) [1] - The average number of collaborative projects per enterprise increased to approximately 2.3 in 1H25, compared to 2.1 in 1H24 [1] Dividend Policy - The company plans to distribute a dividend of 0.1166 yuan per share, with a total dividend payout of 85.615 million yuan, representing a payout ratio of approximately 55% [2] Product Development - The company launched AI products such as MedSeeker, MedPaper, and MedAssister, aimed at assisting physicians in clinical decision-making and improving research efficiency [3] - A new content generation module for pharmaceutical clients was introduced, which can reduce labor costs by 50% while ensuring content professionalism and compliance [3] Valuation and Forecast - The company maintains its target price at 17.5 HKD, based on a 39x EV/EBIT valuation for 2025, with a current trading multiple of approximately 28x [3]

Core Viewpoint - The stock of Yimaitong (02192) experienced a decline of over 5% during trading, currently down 4.3% at HKD 14.02, with a trading volume of HKD 32.4476 million [1] Financial Performance - For the six months ending June 30, 2025, Yimaitong reported revenue of RMB 312 million, representing a year-on-year increase of 28.2% [1] - The profit attributable to the owners of the parent company was RMB 155 million, reflecting a year-on-year increase of 5.9% [1] - Basic earnings per share were reported at 21.2 cents [1] Dividend Announcement - The board of directors declared an interim dividend of RMB 11.66 cents per ordinary share, compared to RMB 12.05 cents in the same period last year [1]

Group 1 - The core viewpoint of the article indicates that 医脉通 (Medlinker) experienced a decline in stock price despite reporting positive financial results for the six months ending June 30, 2025 [1] - The company reported a revenue of 312 million RMB, representing a year-on-year increase of 28.2% [1] - The net profit attributable to the parent company was 155 million RMB, which is a 5.9% increase compared to the previous year [1] - The basic earnings per share were reported at 21.2 cents [1] Group 2 - The board of directors declared an interim dividend of 11.66 cents per ordinary share, down from 12.05 cents in the same period last year [1] - The stock price of 医脉通 fell over 5% during trading, with a current price of 14.02 HKD and a trading volume of 32.4476 million HKD [1]

Core Viewpoint - The company reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong financial performance and growth potential in the market [1] Financial Performance - Revenue reached approximately 312 million RMB, representing a year-on-year growth of 28.2% [1] - Profit attributable to the owners of the parent company was approximately 155 million RMB, showing a year-on-year increase of 5.9% [1] - Adjusted net profit under non-Hong Kong Financial Reporting Standards was about 167 million RMB, reflecting a year-on-year growth of 6.9% [1] - Basic earnings per share were reported at 21.2 cents [1] - The company declared an interim dividend of 11.66 cents per ordinary share [1]

Core Viewpoint - The company, 医脉通 (02192), announced a mid-term dividend of HKD 0.1166 per share for the six months ending June 30, 2025, to be distributed on September 25, 2025 [1] Summary by Category - **Dividend Announcement** - The mid-term dividend is set at HKD 0.1166 per share [1] - The dividend distribution date is scheduled for September 25, 2025 [1] - The dividend pertains to the financial period ending June 30, 2025 [1]

Core Viewpoint - The company, Yimaitong (02192), reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong financial performance and growth potential in the healthcare sector [1]. Financial Performance - The company achieved a revenue of 312 million RMB, representing a year-on-year increase of 28.2% [1]. - The profit attributable to shareholders was 155 million RMB, which is a 5.9% increase compared to the previous year [1]. - The basic earnings per share were reported at 21.2 cents [1].

Group 1 - The company, 医脉通 (02192), reported revenue of 312 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 28.2% [1] - The profit attributable to the owners of the parent company was 155 million RMB, reflecting a year-on-year increase of 5.9% [1] - The basic earnings per share were 21.2 cents [1]